INS and Hypoglycemia: The post hoc analyses presented here indicate that saxagliptin used as an add-on to another non-insulin antihyperglycaemic agent (except perhaps a sulphonylurea) can achieve large decreases in HbA1c with minimal risk of hypoglycaemia.